Those who require insulin pumps could find the approval of the Medtronic MiniMed 670G system by the FDA to be a monumental step forward in helping to improve diabetes care.
The Medtronic MiniMed 670G is designed as the first Hybrid Closed Loop insulin delivery system that will provide substantial support for those with Type 1 diabetes.
The Medtronic MiniMed 670G works by being worn on the body and work to continuously monitor a person's blood-glucose level. Unlike traditional insulin pumps, the Medtronic MiniMed 670G can automatically adjust the level of insulin needed thanks to the SmartGuard HCL algorithm.
The Medtronic MiniMed 670G system features a battery that will last for up to seven days and is expected to be commercially released in the spring of 2017.
Wearable Hybrid Insulin Pumps
The Medtronic MiniMed 670G Monitors Blood-Glucose Levels and More
Trend Themes
1. Hybrid Closed Loop Insulin Delivery Systems - The development of hybrid closed loop insulin delivery systems like the Medtronic MiniMed 670G presents an opportunity for disruption in diabetes care.
2. Continuous Glucose Monitoring - Advancements in continuous glucose monitoring technology, as seen in the Medtronic MiniMed 670G, have the potential to revolutionize diabetes management.
3. Smart Algorithms for Insulin Adjustment - The use of smart algorithms, such as the SmartGuard HCL algorithm in the Medtronic MiniMed 670G, could lead to more precise and automated insulin adjustment for individuals with diabetes.
Industry Implications
1. Medical Device Manufacturing - The development of wearable hybrid insulin pumps creates opportunities for disruptive innovation in the medical device manufacturing industry.
2. Healthcare Technology - Continuous glucose monitoring and smart algorithms for insulin adjustment have the potential to drive innovation in the healthcare technology industry.
3. Diabetes Management - Advancements in hybrid closed loop insulin delivery systems offer disruptive innovation opportunities in the field of diabetes management.